Oncology & Hematology

Oncology Open Day

April 17, 2024 Exclusive Opportunity: Oncology Consulting Session Discover a unique opportunity to participate in one-on-one discussions with Premier Research experts. Our specialists in oncology will be accessible on specific dates for personalized consultations. Seize this opportunity to acquire valuable insights. Secure your spot by signing up now.

Transformative Advances in Cancer Immunotherapy: Progress and Promise

Immunotherapy, which engages and harness the body’s own immune system to fight cancer, has revolutionized the field of oncology. Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. These approaches all seek to elicit a T-cell-based immune response against tumor antigens,...

ASCO

June 1 – 3, 2024 Chicago, Illinois Booth #35157 Visit our booth at ASCO for an exclusive look at our latest advancements in oncology. Connect with our experts, explore innovative solutions, and be part of the future of cancer research. See you there!

Clinical Research: Phase 1 - Phase 4

Patient-Centered Hematological Malignancy Trials: A Blueprint for Success 

Hematological malignancies are a diverse group of cancers that affect the blood, bone marrow, lymph nodes, and spleen. The complexity and variability of these diseases demand innovative and personalized approaches to treatment that traditional clinical trial methodologies often lack. Designing patient-centric hematology clinical trials requires a comprehensive understanding of the patient experience, coupled with a...

Clinical Research: Phase 1 - Phase 4

Getting It Right from the Start: 10 Essentials for Designing Biomarker-Guided Oncology Clinical Studies

In the field of oncology, as we got better at understanding the changes that occur in cancers at a molecular level, we have seen a shift towards precision medicine. Biomarkers are central to this change and can be leveraged to provide important insights at every stage of drug development. By advancing our understanding of cancer...

Clinical Research: Phase 1 - Phase 4

Operationalizing Biomarker-Guided Oncology Trials: Planning for Success

Advances in genomic and proteomic technologies have led to the identification of numerous biomarkers with potential clinical utility in oncology, including gene mutations, gene amplifications, gene expression signatures, and altered proteins. To date, more than 1,500 potential oncology biomarkers have been identified in the preclinical setting. Among these, approximately half are being studied in active...

Clinical Research: Phase 1 - Phase 4

Regulatory Considerations for Radiotherapeutics and Radiodiagnostics

Scientific innovation and advances in ligand targeting have spurred the development of many different types of radiopharmaceuticals (RPs) – radioisotopes bound to biological molecules to target specific organs, tissues, or cells within the body — with a wide range of clinical uses. As those uses have proliferated, and as research has continued to yield novel...

Clinical Research: Phase 1 - Phase 4

The Multi-Faceted World of Clinical Trial Matching in Precision Oncology Studies

The success of clinical trials is contingent upon finding participants who meet certain criteria, ensuring that the resulting study data are meaningful and relevant to the target patient population. Clinical trial matching is the process of identifying and connecting potential participants with studies that align with their specific medical condition and characteristics. In precision oncology,...

Clinical Research: Phase 1 - Phase 4

Vein-to-Vein Logistics in Cell Therapy: A Guide to Reducing Workflow Risk from Engineering to Patients’ Bedside

Cell therapy clinical trials are complex and successfully operationalizing these studies requires careful consideration of the interplay between the patient journey and vein-to-vein logistics workflow. In this guide, we explore key steps in executing a cell therapy clinical trial, from selecting the right sites to optimizing study retention. We also discuss the critical role of...

Medical and Regulatory Affairs

Rare Oncology and the FDA: Taking the Guesswork Out of Expedited Pathways

Rare cancers account for 25-30 percent of all new cancer diagnoses and 25 percent of cancer deaths.1 With their poorly understood natural histories, phenotypic heterogeneity, and diverse clinical manifestations, rare cancers pose challenges to drug development and represent a significant unmet need in oncology. Faced with limited treatment options, researchers, clinicians, and patients may be...